Galderma Receives FDA Approval for Restylane® Defyne for Chin Augmentation
Galderma announces that the U.S. Food and Drug Administration (FDA) has...
Read More
PRIME Journal is part of the Informa Markets Division of Informa PLC
PRIME Journal is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
